Skip to main content
PLOS One logoLink to PLOS One
. 2022 Jan 4;17(1):e0257967. doi: 10.1371/journal.pone.0257967

Adenylate kinase 1 overexpression increases locomotor activity in medaka fish

Michiyo Maruyama 1,2, Yuko Furukawa 2, Masato Kinoshita 3, Atsushi Mukaiyama 4,5, Shuji Akiyama 4,5, Takashi Yoshimura 1,2,*
Editor: Hubert Vaudry6
PMCID: PMC8726475  PMID: 34982774

Abstract

Maintenance of the energy balance is indispensable for cell survival and function. Adenylate kinase (Ak) is a ubiquitous enzyme highly conserved among many organisms. Ak plays an essential role in energy regulation by maintaining adenine nucleotide homeostasis in cells. However, its role at the whole organism level, especially in animal behavior, remains unclear. Here, we established a model using medaka fish (Oryzias latipes) to examine the function of Ak in environmental adaptation. Medaka overexpressing the major Ak isoform Ak1 exhibited increased locomotor activity compared to that of the wild type. Interestingly, this increase was temperature dependent. Our findings suggest that cellular energy balance can modulate locomotor activity.

Introduction

Energy homeostasis is crucial for survival and the maintenance of cell function. Disruption of energy balance is suggested to be associated with many conditions, including obesity, heart failure, and neurodegeneration [14]. Adenylate kinase (Ak) is an essential enzyme found in nearly every organism because of its crucial role in cellular energy metabolism [47]. Ak catalyzes the nucleotide phosphoryl exchange reaction (2ADP ↔ ATP + AMP) to maintain the adenine nucleotide balance and monitor energy consumption. Ak and its downstream adenine nucleotide signaling pathway have attracted attention because of their vital functions in many biological processes, such as the cell cycle, hormone secretion, and stress tolerance [5,711]. To date, nine isoforms of AK (AK1–AK9) have been identified and well characterized in humans [6] (Fig 1A). AK1 is the major isoform of AK and is expressed in the cytosol of most human tissues, with particularly high levels in the brain, the heart, skeletal muscles, and erythrocytes. Several reports have demonstrated the importance of Ak1 in metabolic stress conditions [911]. Interestingly, it was recently reported that hyperactive rat strains exhibit increased Ak1 expression [12]. To our knowledge, however, the role of Ak1 at the whole organism level, especially in animal behavior, remains unclear.

Fig 1. Generation of Ak1-overexpressing medaka.

Fig 1

(A) Phylogenetic tree showing the relationship of the AK isozymes of human, mouse and medaka. (B) Electrophoresis image of Ak1 and Actb RT-PCR products in various adult medaka tissues. B, Brain; E, Eye; O, Ovary; L, Liver; S, Skin; N, No-template control. (C) Structure of Ak1 overexpression construct. The construct consisted of the medaka Actb regulatory region, Ak1 cDNA (without the stop codon), C-terminus 3× FLAG tag, internal ribosome entry site (IRES), green fluorescent protein (GFP) open reading frame, and SV40 polyA signal. (D) Design of genetic crosses for generating heterozygous Ak1-overexpressing (Ak1-OE) medaka and their wild-type (WT) siblings. (E) Bright-field and fluorescence images of WT and Ak1-OE embryos at 5 days post-fertilization (dpf). (F) Ak1 expression level of larvae at 9 dpf. Data represent the mean ± SEM, n = 4 each. WT expression level was set at 1. The p-value was calculated using two-tailed Welch’s t-test. Each dot represents an individual value. (G) Western blotting for Ak1 (left) and FLAG tag (right). Black and white arrows indicate Ak1-FLAG and Ak1, respectively.

In this study, we sought to clarify the effect of Ak1 on animal behavioral rhythms. The medaka (Oryzias latipes), a small freshwater fish, has recently emerged as a useful vertebrate model because of its small size and short generation time. Additionally, there are well-established methods for transgenic and genomic editing in medaka. Behavioral assays are also well established, for both medaka and zebrafish, but medaka can survive a wider range of water temperatures (4–40°C) than zebrafish (20–32°C), and they exhibit seasonal behavioral patterns [1316]. Therefore, the medaka is an excellent model with which to investigate adaptive strategies to environmental changes.

Here, we successfully established Ak1-overexpressing (Ak1-OE) medaka. Behavioral assays of Ak1-OE medaka larvae revealed a temperature-dependent increase in locomotor activity. These findings shed new light on the function of Ak1.

Materials and methods

Ethics statement for animal experiments

All animal studies were performed in accordance with the ARRIVE guidelines. All methods were conducted in compliance with the relevant guidelines and regulations and were approved by the Animal Experiment Committee of Nagoya University (approved number: AGR2020009). Animals were euthanized with ethyl 3-aminobenzoate methanesulfonate (MS-222) before sampling. All efforts were made to minimize animal suffering.

Animals

Medaka fish (Oryzias latipes) were obtained from a local dealer (Fuji 3A Project, Nagoya, Japan). The fish were maintained in a housing system (MEITO system; Meito Suien, Nagoya, Japan) under a 14 h light/10 h dark photoperiod (lights on at 05:00 and off at 19:00) at a water temperature of 25°C. They were fed twice a day with Hikari Labo 450 (KYORIN, Tokyo, Japan).

Phylogenetic analysis

The phylogenetic tree was constructed using the maximum likelihood method with MEGA 11 (https://www.megasoftware.net/). The GenBank accession numbers of the nucleotide sequences used for the phylogenetic analysis are as follows:

Human (Homo sapiens) AK1, NM_000476.3; Mouse (Mus musculus) Ak1, NM_001198790.1; Medaka (Oryzias latipes) Ak1, XM_004074742.4; Human AK2, NM_001199199.3; Mouse Ak2, NM_001033966.4; Medaka Ak2, XM_011481017.3; Human AK3, NM_001199852.2; Mouse Ak3, NM_001365071.1; Medaka Ak3, XM_004074841.4; Human AK4, NM_001005353.3; Mouse Ak4, NM_001177602.1; Medaka Ak4, XM_004068018.4; Human AK5, NM_012093.4, Mouse Ak5, NM_001081277.2; Medaka Ak5, XM_004078698.4; Human AK6, NM_001015891.2; Mouse Ak6, NM_027592.3; Medaka Ak6, XM_004072821.3; Human AK7, NM_001350888.2; Mouse Ak7, NM_030187.1; Medaka Ak7, XM_011490546.3; Medaka LOC101157414, XM_011492034.2; Human AK8, NM_001317958.2; Mouse Ak8, NM_001033874.2; Medaka Ak8, XM_023958761.1; Human AK9, NM_001145128.3; Mouse Ak9, NM_001370813.1; Medaka Ak9, XM_020714548.2

Gene expression analysis

Total RNA was purified using an RNeasy micro kit (Qiagen, Hilden, Germany) with DNase I. Extracted RNA was stored at –80°C. Reverse transcription was performed on total RNA (200 ng) using a ReverTra Ace qPCR RT Master Mix (Toyobo, Osaka, Japan).

RT-PCR was performed using TaKaRa Ex Taq (Takara Bio Inc., Shiga, Japan) and the following primers: Ak1 forward (F): 5’-ACACTCACCTGTCTTCAGGC-3’ and reverse (R): 5’-CTGTGTCCAGGGGTACAAGC-3’, and Actb F: 5’-GATTCCCTTGAAACGAAAAGCC-3’ and R: 5’-CAGGGCTGTTGAAAGTCTCAAAC-3’. Amplification was conducted at 94°C for 2 min, followed by 30 cycles of 98°C for 10 s, 60°C for 30 s, 72°C for 30 s and 72°C for 5 min. The PCR products were analyzed using a MultiNA microchip electrophoresis system (Shimadzu Corporation, Kyoto, Japan).

For real-time quantitative PCR (qPCR), 2 μL of the synthesized cDNA was mixed with SYBR Premix Ex Taq II (Takara Bio Inc.) and 0.4 μM primers (same as above) to a total volume of 20 μL. qPCR was performed on a QuantStudio 3 Real-Time PCR System (Applied Biosystems, Waltham, MA, USA). The Actb gene was used as an internal control.

Construction of Ak1-OE plasmid

Total RNA was purified from embryos at 4 dpf using an RNeasy micro kit (Qiagen) with DNase I. Reverse transcription of total RNA (200 ng) was performed using a ReverTra Ace qPCR RT kit (Toyobo). The entire Ak1 open reading frame (excluding the stop codon) was amplified by PCR (98°C for 2 min; 35 cycles of 98°C for 10 s, 65°C for 30 s, 72°C for 1 min, and 72°C for 5 min) using a Q5 Hot Start High-Fidelity 2× Master Mix (New England Biolabs, Ipswich, MA, USA) and primers containing the restriction sites of SpeI or BglII for subsequent subcloning (F: 5’-CCACTAGTATGGCAGACAAAATCAAGGAC-3’ and R: 5’- CCAGATCTCTTCAGTGAATCAATAGCCTG-3’).

The overexpression plasmid contained the Actin β (Actb) promoter followed by the first noncoding exon and the first intron, a 3×FLAG tag, an internal ribosomal entry site (IRES), GFP and SV40 polyA sequences in the NotI-NotI interval [17]. Ak1 cDNA and plasmids were digested with SpeI and BglII and purified using NucleoSpin Gel and PCR Clean-up (Macherey-Nagel, Düren, Germany). Ligation was performed using Ligation High Ver. 2 (Toyobo). The sequence of the constructs was confirmed by direct sequencing.

Generation of Ak1-OE medaka

The NotI-NotI interval of the Ak1-OE plasmid was purified and diluted with sterilized water (final concentration: 20 ng/μL) and then microinjected into the cytoplasm of one-cell stage embryos (F0). F0 fish with mosaic GFP fluorescence were raised and crossed with WT fish to obtain heterozygous transgene carriers (F1). F1 fish with GFP fluorescence were crossed with the WT fish. Heterozygous F2 offspring were used for behavioral experiments.

Western blot analysis

Frozen 9 dpf larvae were homogenized and sonicated in 4× Laemmli sample buffer (Bio-Rad, Hercules, CA, USA). Samples were quantified using Pierce 660 nm Protein Assay Reagent (Thermo Fisher Scientific, Waltham, MA, USA). Twenty-five micrograms of protein per sample were separated by SDS-PAGE and transferred onto a PVDF membrane. The PVDF membrane was blocked with 5% skim milk in Tris-buffered saline with Tween 20 (TBST) for 1 h at room temperature. Ak1 polyclonal primary antibody (1:500) (14978-1-AP; Proteintech, Rosemont, IL, USA) was dissolved in 5% skim milk in TBST and incubated for 1 h at room temperature. After washing the membrane with TBST, the membranes were incubated with secondary rabbit antibody (1:1000) (NA934-100UL; GE Healthcare, Chicago, IL, USA) dissolved in 5% skim milk in TBST for 1 h at room temperature. The membrane was washed with TBST and incubated with ECL prime (GE Healthcare) for 5 min at room temperature and imaged on a LuminoGraph II EM (ATTO, Tokyo, Japan). After eliminating signals using hydrogen peroxide, the membrane was treated with FLAG (DDDDK) tag primary monoclonal antibody (1:1000) (M185-3S; MBL, Nagoya, Japan) followed by secondary mouse antibody (1:1000) (NA931-100UL; GE Healthcare).

Behavioral assays

F2 Ak1-OE and WT embryos were incubated under a 14L10D cycle at 25°C until hatching. To measure the locomotor activity, at the end of the light phase at 8 dpf, Ak1-OE larvae and their WT siblings were distributed among 48 round well plate (CELL STAR; Greiner Bio-One, Kremsmünster, Austria) each containing 1200 μL of water, with 1 larva per well. The plate was then installed in a DanioVision Observation Chamber (Noldus, Wageningen, the Netherlands). At 19:00 8 dpf, the light was turned off and the larvae were acclimated for 10 h during the dark phase. Behavior was recorded from 05:00 9 dpf to 5:00 12 dpf (for 3 days) under a 14 h light (300 lx) and 10 h dark (0 lx) photoperiod (lights on at 05:00 and off at 19:00) at a water temperature of 15 or 25°C. Behavior was recorded at 3.75 frames per second and analyzed using the tracking software EthoVision XT (Noldus). Locomotor activity was calculated by measuring the “distance moved” every 10 min.

To examine thigmotaxis, we referred to Schnörr et al. [18]. In brief, larvae were transferred to a 24-well round plate (Nunclon Delta Surface; Thermo Fisher Scientific, Waltham, MA, USA) at 8 dpf. The plate was then installed in a DanioVision Observation Chamber at 9 dpf. After 6 min of acclimation phase (light on), the lights were kept off for 4 min and activities were recorded. The experiments were conducted from 10:00 to 12:00 at 9 dpf. To examine scototaxis and geotaxis, we conducted a light-dark tank test and a novel tank test, respectively [19]. In these assays, adult fish (> 6 months) were used. For the novel tank test, each fish was introduced into a glass tank (100 mm width × 65 mm depth × 142 mm height) filled with water to a height of 100 mm. Recordings were started immediately after transferring the fish and lasted for 7 min. We excluded the first 1 min from the analysis. For the light-dark tank test, a plastic container (150 mm width × 100 mm depth × 55 mm height) was used. The container was divided into two equal-sized sections, colored either white or black. Fish were placed in the light area and allowed to move freely between the dark and light areas for 16 min. We excluded the first 1 min from the analysis.

Statistical analysis

Data are presented as the mean ± SEM generated using the statistical software GraphPad Prism 9. Two-tailed Welch’s t-test was used for comparisons between two groups. For comparisons among three or more groups, two-way ANOVA and post hoc tests were conducted using GraphPad Prism 9.

Results

Generation of Ak1-OE medaka

We first examined Ak1 expression in various medaka tissues. Reverse transcription polymerase chain reaction (RT-PCR) results showed widespread expression (Fig 1B). To evaluate the effect of constitutively high Ak1 expression, we used a construct that overexpressed Ak1 in response to regulation of the Actb promoter (Fig 1C). This construct enabled us to visualize transgene expression via green fluorescent protein (GFP), which was linked to the 3’ internal ribosome entry site (IRES) downstream of Actb-Ak1 [17].

To generate Ak1-OE medaka, the construct was microinjected into the cytoplasm of one-cell stage embryos. Exhibiting chimeric GFP expression embryos were raised as F0 medaka. These medaka were paired with the wild type to obtain heterozygous transgene carriers (F1). GFP-expressing F1 medaka were then crossed with the wild type to generate heterozygous F2 offspring (Fig 1D and 1E). Overexpression of Ak1 in GFP-positive F2 medaka was confirmed by quantitative RT-PCR (qPCR) (Fig 1F). We also determined Ak1 protein levels in both Ak1-OE and WT by western blot analysis using the Ak1 antibody (Fig 1G, left). In both Ak1-OE and WT samples, we observed bands close to the expected band size of medaka Ak1 (21.4 kDa). In addition, we found strong bands at high molecular weights only in Ak1-OE samples. In our overexpression construct, we added a 3× FLAG tag downstream of the Ak1 sequence. Therefore, we expected that the strong bands observed were FLAG-tagged Ak1. To confirm this, we examined western blot analysis using a FLAG-tag antibody. As expected, we observed bands at the same position as those detected with the Ak1 antibody (Fig 1G, right). From these results, we confirmed Ak1 overexpression at both the gene expression and protein levels.

Ak1-OE larvae exhibited increased locomotor activity at 25°C

The high-throughput behavioral tracking assay is well established in larvae of zebrafish and medaka fish [14,15]. Therefore, we used this method to examine the locomotor activity of medaka larvae. Ak1-OE embryos and their wild-type (WT) siblings were raised in an incubator under a 14 h light/10 h dark (14L10D) cycle (lights on at 05:00 and off at 19:00) at 25°C. At the end of the light phase at 8 days post-fertilization (dpf), hatched larvae were placed in each well of a 48-well plate. The plate was then put into a high-throughput behavior tracking system. Larvae were maintained under a 14L10D cycle at 25°C. After 10 h of habituation, at the onset of the light phase at 9 dpf, locomotor activity was tracked for three full days (Fig 2A). The tracking profiles showed that both Ak1-OE and WT larvae were more active during the light phase than during the dark phase (Fig 2B). Compared to that on the first day of the assay, the total distance moved by the WT larvae significantly decreased on the third day (Fig 2C). As in previous studies [14,15], larvae were not fed during the assay to avoid interrupting it. This may have caused decreased energy, and hence, decreased activity, later in the experiment. Notably, the average locomotor activity of the Ak1-OE larvae tended to be higher than that of the WT larvae throughout the assay. This trend was particularly obvious on day 3, at which point the total locomotor activity of the Ak1-OE larvae was significantly higher than that of the WT larvae, both in the light and dark phases (Fig 2D).

Fig 2. Locomotor activity of Ak1-overexpressing larvae at 25°C.

Fig 2

(A) Structure of the behavioral assay. Larvae (8 dpf) were placed into a photoperiod- and temperature-controlled chamber (14L10D, 25°C) at the end of the light phase. After 10 h of habituation (Hab.), recording was started at the onset of the light phase at 9 dpf and continued for 3 full days. (B) Mean locomotor activity of Ak1-overexpressing (Ak1-OE) and wild-type (WT) larvae. (C) Total locomotor activity of Ak1-OE and WT larvae per day. Data represent the mean ± SEM and were analyzed via two-way repeated measures ANOVA. Effect of time, F(1.386, 37.43) = 11.45, p = 0.0006; effect of overexpression, F(1, 27) = 7.891, p = 0.0091; effect of interaction, F(2, 54) = 0.2186, p = 0.8044. *p < 0.05; n.s., not significant (Dunnett’s multiple comparisons test, vs. day 1). (D) Total locomotor activity of Ak1-OE and WT larvae per day during the light phase (white) and dark phase (gray). Data represent the mean ± SEM. The p-values (*p < 0.05) were calculated using two-tailed Welch’s t-test. Each dot represents an individual value. (B–D) n = 15 (WT), n = 14 (Ak1-OE).

To test whether the increase in locomotor activity of Ak1-OE was due to changes in some taxis, we conducted several additional behavioral tests. When we examined changes in thigmotaxis between Ak1-OE and WT as described by Schnörr et al. [18], no difference was observed (S1A and S1B Fig). We also conducted a light-dark tank test (S1C and S1D Fig) and a novel tank test (S1E and S1F Fig) for scototaxis and geotaxis, respectively. However, we found no difference between Ak1-OE and WT in these tests, suggesting that Ak1 indeed affects locomotor activity but not taxis.

Ak1-OE larvae did not exhibit increased locomotor activity at 15°C

Ambient temperature directly affects the metabolic rate of ectothermic animals. Therefore, we further examined the locomotor activity of Ak1-OE larvae at a lower temperature (15°C), a condition associated with lower energy expenditure. After they were raised at 25°C, at 8 dpf, larvae were placed in a tracking chamber and exposed to a 14L10D cycle at 15°C (Fig 3A). In both the Ak1-OE and WT larvae, locomotor activity levels on days 2 and 3 were similar to those on day 1 (Fig 3B and 3C). This suggests that the larvae conserved their energy until the end of the experiment at the lower temperature. Unlike the results at 25°C, there was no difference in locomotor activity between the Ak1-OE and WT larvae throughout the experiment (Fig 3D). This suggests that the increase in the locomotor activity of Ak1-OE larvae was temperature dependent.

Fig 3. Locomotor activity of Ak1-overexpressing larvae at 15°C.

Fig 3

(A) Structure of the behavioral assay. Larvae were maintained in a chamber under a 14L10D cycle at 15°C. (B) Mean locomotor activity of Ak1-overexpressing (Ak1-OE) and wild-type (WT) larvae. (C) Total locomotor activity of Ak1-OE and WT larvae per day. Data represent the mean ± SEM and were analyzed via two-way repeated measures ANOVA. Effect of time, F(1.910, 68.74) = 1.848, p = 0.1669; effect of overexpression, F(1, 36) = 3.607×10−5, p = 0.9952; effect of interaction, F(2, 72) = 0.2813, p = 0.7556. n.s., not significant (Dunnett’s multiple comparisons test, vs. day 1). (D) Total locomotor activity of Ak1-OE and WT larvae per day during the light phase (white) and dark phase (gray). Data represent the mean ± SEM. n.s., not significant (two-tailed Welch’s t-test). Each dot represents an individual value. (B–D) n = 20 (WT), n = 18 (Ak1-OE).

Discussion

Ak are essential enzymes that play critical roles in metabolic monitoring and signaling of cells. Among the Ak family members, we focused on Ak1, the major cytosolic isoform of Ak. In the present study, in various medaka tissues, we observed Ak1 expression similar to that reported in other animals [6] (Fig 1B). Ak1 is highly conserved among many organisms. Indeed, the alignment of human AK1 (NP_000467.1, 194 aa) with medaka Ak1 (XP_004074790.1, 194 aa) exhibited 75% identical residues and 88% similar residues (via the NCBI BLAST Needleman-Wunsch Global Align function).

To know the function of Ak1 at the whole organism level, we established an Ak1-OE medaka line (Fig 1C–1G). Behavioral assays of the medaka larvae revealed that Ak1-OE larvae exhibited increased locomotor activity compared with that of the WT larvae at 25°C, and the difference between the Ak1-OE and WT larvae was most obvious on the last day of the experiment (Fig 2D). Ak1-OE larvae maintained a higher activity level throughout the entire experiment, whereas the total amount of locomotor activity of the WT larvae significantly decreased on day 3 (Fig 2C). In contrast, throughout the experiment at 15°C, the locomotor activity of Ak1-OE larvae did not differ from that of the WT larvae (Fig 3D). Several knockout studies have shown that Ak1 deficiency can be compensated for by other members of the Ak family under normal conditions, whereas Ak1 deficiency leads to failure of metabolic homeostasis under stress conditions [10,11,20]. As our behavioral assays were conducted without feeding, the lack of energy later in the experiment might have mimicked metabolic stress even at the moderate temperature of 25°C, and this could have caused the large difference in activity between the Ak1-OE and WT larvae on the last day of the assay.

In summary, Ak1 is known to play crucial roles in cell function. Our results indicate the importance of Ak1 not only at the cellular level but also at the behavioral level.

Supporting information

S1 Fig. Comparison of thigmotaxis, scototaxis, and geotaxis between Ak1-OE and WT.

(A) Schematic drawing of thigmotaxis measurement test. (B) Results of thigmotaxis measurement test (n = 11 each). (C) Schematic of light-dark tank test. (D) Results of light-dark tank test (n = 8 each). (E) Schematic representation of the novel tank test. (F) Results of the novel tank test (n = 8 each). All data are presented as the mean ± SEM. The p-value was calculated using a two-tailed Welch’s t-test. Each dot represents an individual value.

(TIF)

S1 Raw images

(PDF)

Acknowledgments

We thank Drs. T. Nishiwaki-Ohkawa, A. Shinomiya and T. Nakayama for helpful discussions. We also thank A. Ieda and A. Matsumiya for technical assistance.

Data Availability

All relevant data are within the paper and its Supporting Information files.

Funding Statement

This work was supported by a JSPS KAKENHI “Grant-in-Aid for Scientific Research (S)” (19H05643) for T.Y. and the Sasakawa Scientific Research Grant from The Japan Science Society for M.M. There was no additional external funding received for this study. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Wells JCK, Siervo M. Obesity and energy balance: Is the tail wagging the dog? Eur J Clin Nutr. 2011;65: 1173–1189. doi: 10.1038/ejcn.2011.132 [DOI] [PubMed] [Google Scholar]
  • 2.Ventura-Clapier R, Garnier A, Veksler V. Energy metabolism in heart failure. J Physiol. 2004;555: 1–13. doi: 10.1113/jphysiol.2003.055095 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Błaszczyk JW. Energy metabolism decline in the aging brain—pathogenesis of neurodegenerative disorders. Metabolites. 2020. pp. 1–20. doi: 10.3390/metabo11010001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Ionescu MI. Adenylate Kinase: A ubiquitous enzyme correlated with medical conditions. Protein J. 2019;38: 120–133. doi: 10.1007/s10930-019-09811-0 [DOI] [PubMed] [Google Scholar]
  • 5.Dzeja P, Terzic A. Adenylate kinase and AMP signaling networks: metabolic monitoring, signal communication and body energy sensing. Int J Mol Sci. 2009;10: 1729–1772. doi: 10.3390/ijms10041729 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Panayiotou C, Solaroli N, Karlsson A. The many isoforms of human adenylate kinases. Int J Biochem Cell Biol. 2014;49: 75–83. doi: 10.1016/j.biocel.2014.01.014 [DOI] [PubMed] [Google Scholar]
  • 7.Klepinin A, Zhang S, Klepinina L, Rebane-Klemm E, Terzic A, Kaambre T, et al. Adenylate kinase and metabolic signaling in cancer cells. Front Oncol. 2020;10: 1–9. doi: 10.3389/fonc.2020.00001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Karl Olson L, Schroeder W, Paul Robertson R, Goldberg ND, Walseth TF. Suppression of adenylate kinase catalyzed phosphotransfer precedes and is associated with glucose-induced insulin secretion in intact HIT-T15 cells. J Biol Chem. 1996;271: 16544–16552. doi: 10.1074/jbc.271.28.16544 [DOI] [PubMed] [Google Scholar]
  • 9.Janssen E, Dzeja PP, Oerlemans F, Simonetti AW, Heerschap A, De Haan A, et al. Adenylate kinase 1 gene deletion disrupts muscle energetic economy despite metabolic rearrangement. EMBO J. 2000;19: 6371–6381. doi: 10.1093/emboj/19.23.6371 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Dzeja PP, Bast P, Pucar D, Wieringa B, Terzic A. Defective metabolic signaling in adenylate kinase AK1 gene knock-out hearts compromises post-ischemic coronary reflow. J Biol Chem. 2007;282: 31366–31372. doi: 10.1074/jbc.M705268200 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Xie M, Zhang G, Zhang H, Chen F, Chen Y, Zhuang Y, et al. Adenylate kinase 1 deficiency disrupts mouse sperm motility under conditions of energy stress. Biol Reprod. 2020;103: 1121–1131. doi: 10.1093/biolre/ioaa134 [DOI] [PubMed] [Google Scholar]
  • 12.Horiguchi T, Miyatake Y, Miyoshi K, Tanimura A, Hagita H, Sakaue H, et al. Gene-expression profile reveals the genetic and acquired phenotypes of hyperactive mutant SPORTS rat. J Med Investig. 2020;67: 51–61. doi: 10.2152/jmi.67.51 [DOI] [PubMed] [Google Scholar]
  • 13.Nakayama T, Okimura K, Shen J, Guh YJ, Katherine Tamai T, Shimada A, et al. Seasonal changes in NRF2 antioxidant pathway regulates winter depression-like behavior. Proc Natl Acad Sci U S A. 2020;117: 9594–9603. doi: 10.1073/pnas.2000278117 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Fontinha BM, Zekoll T, Al-Rawi M, Gallach M, Reithofer F, Barker AJ, et al. TMT-Opsins differentially modulate medaka brain function in a context-dependent manner. PLoS Biol. 2021; 19: e3001012. doi: 10.1371/journal.pbio.3001012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Rihel J, Prober DA, Arvanites A, Lam K, Zimmerman S, Jang S, et al. Zebrafish behavioral profiling links drugs to biological targets and rest/wake regulation. Science. 2010;327: 348–351. doi: 10.1126/science.1183090 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Wittbrodt J, Shima A, Schartl M. Medaka—A model organism from the far east. Nat Rev Genet. 2002; 3: 53–64. doi: 10.1038/nrg704 [DOI] [PubMed] [Google Scholar]
  • 17.Fukamachi S, Yada T, Meyer A, Kinoshita M. Effects of constitutive expression of somatolactin alpha on skin pigmentation in medaka. Gene. 2009;442: 81–87. doi: 10.1016/j.gene.2009.04.010 [DOI] [PubMed] [Google Scholar]
  • 18.Schnörr SJ, Steenbergen PJ, Richardson MK, Champagne DL. Measuring thigmotaxis in larval zebrafish. Behav Brain Res. 2012;228: 367–374. doi: 10.1016/j.bbr.2011.12.016 [DOI] [PubMed] [Google Scholar]
  • 19.Nakayama T, Shimmura T, Shinomiya A, Okimura K, Takehana Y, Furukawa Y, et al. Seasonal regulation of the lncRNA LDAIR modulates self-protective behaviours during the breeding season. Nat Ecol Evol. 2019;3: 845–852. doi: 10.1038/s41559-019-0866-6 [DOI] [PubMed] [Google Scholar]
  • 20.Pucar D, Janssen E, Dzeja PP, Juranic N, Macura S, Wieringa B, et al. Compromised energetics in the adenylate kinase AK1 gene knockout heart under metabolic stress. J Biol Chem. 2000;275: 41424–41429. doi: 10.1074/jbc.M007903200 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Hubert Vaudry

27 Oct 2021

PONE-D-21-29550Adenylate kinase 1 overexpression increases locomotor activity in medaka fishPLOS ONE

Dear Dr. Yoshimura,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Your manuscript has been evaluated by two reviewers who are recognized experts in this field. Both reviewers made recommendations that you should consider in order to carefully revise your manuscript.

Please submit your revised manuscript by Dec 11 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Hubert Vaudry

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. To comply with PLOS ONE submissions requirements, in your Methods section, please provide additional information on the animal research and ensure you have included details on (1) methods of sacrifice, (2) methods of anesthesia and/or analgesia, and (3) efforts to alleviate suffering.

3. Thank you for stating in your Funding Statement: 

 [This work was supported in part by a JSPS KAKENHI “Grant-in-Aid for Scientific Research (S)” (19H05643) for T.Y. and the Sasakawa Scientific Research Grant from The Japan Science Society for M.M.]

Please provide an amended statement that declares *all* the funding or sources of support (whether external or internal to your organization) received during this study, as detailed online in our guide for authors at http://journals.plos.org/plosone/s/submit-now.  Please also include the statement “There was no additional external funding received for this study.” in your updated Funding Statement. 

Please include your amended Funding Statement within your cover letter. We will change the online submission form on your behalf.

4. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

5. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels. 

  

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: I Don't Know

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This manuscript by Maruyama and colleagues addresses an interesting issue regarding the links between cellular energy metabolism and behavioural activity. Using a medaka transgenic model, the authors study the consequences of overexpression of one key isoform of the enzyme Adenylate kinase (AK1) on locomotor activity of larval medaka following Day 8 post fertilization. The overall basal level of locomotor activity measured in the transgenics appears to be significantly higher than in the wild type controls, but only when measured at 25°C. Instead, during the locomotor activity assay performed at 15°C, activity of the wild type and transgenics were indistinguishable.

This is an interesting observation that deserves to be published, however I would propose the following modifications:

1) It is well know that in teleosts, many gene families are larger than in mammals due to the effect of extra gene copies resulting from ancestral genome duplication events. This leads to the obvious question: are there only 9 isoforms of AK in medaka? If there are more, it would be helpful to include a figure with a phylogenetic tree comparing the mammalian and medaka situation.

2) While it is clear that the AK1 transgene is expressed from a strong, widely expressed promoter, there is no evidence provided comparing AK1 protein levels or AK1 enzymatic activity in the transgenics and wild types. This would be particularly important information to fully interpret the comparison of the behaviour at the two different temperatures. If technically feasible, such extra information would be invaluable for interpreting the results.

Reviewer #2: This manuscript by Maruyama et al. describes the effect of adenylate kinase 1 overexpression on locomotor activity in medaka. The authors found that Ak1-OE increases locomotor activity at a water temperature of 25C in the light period. As such a change did not occur at 15C, the authors suggested the possibility of modulating locomotor activity by Ak1 depending water temperature. This MS was short and well written about well-designed experiments. I have only one question, and changes in locomotor activity may reflect some change in taxis. Did the authors observe any changes in thigmotaxis, scototaxis, geotaxis, etc.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Jan 4;17(1):e0257967. doi: 10.1371/journal.pone.0257967.r002

Author response to Decision Letter 0


3 Dec 2021

Point-by-point responses to the reviewers’ comments to Maruyama et al., “Adenylate kinase 1 overexpression increases locomotor activity in medaka fish”

We are grateful to the reviewers for their positive and valuable comments, which have helped us improve our manuscript. The reviewers’ comments are shown in blue font below, and our responses are shown in black font.

Reviewer #1: This manuscript by Maruyama and colleagues addresses an interesting issue regarding the links between cellular energy metabolism and behavioural activity. Using a medaka transgenic model, the authors study the consequences of overexpression of one key isoform of the enzyme Adenylate kinase (AK1) on locomotor activity of larval medaka following Day 8 post fertilization. The overall basal level of locomotor activity measured in the transgenics appears to be significantly higher than in the wild type controls, but only when measured at 25°C. Instead, during the locomotor activity assay performed at 15°C, activity of the wild type and transgenics were indistinguishable.

This is an interesting observation that deserves to be published, however I would propose the following modifications:

1) It is well known that in teleosts, many gene families are larger than in mammals due to the effect of extra gene copies resulting from ancestral genome duplication events. This leads to the obvious question: are there only 9 isoforms of AK in medaka? If there are more, it would be helpful to include a figure with a phylogenetic tree comparing the mammalian and medaka situation.

Response: Only Ak7 was duplicated in medaka. As suggested, we have added the phylogenetic tree in Fig. 1A. Accordingly, we have changed the figure order.

We have also added the following text in the Methods section:

Phylogenetic analysis

The phylogenetic tree was constructed using the maximum likelihood method with MEGA 11 (https://www.megasoftware.net/). The GenBank accession numbers of the nucleotide sequences used for the phylogenetic analysis are as follows:

Human (Homo sapiens) AK1, NM_000476.3; Mouse (Mus musculus) Ak1, NM_001198790.1; Medaka (Oryzias latipes) Ak1, XM_004074742.4; Human AK2, NM_001199199.3; Mouse Ak2, NM_001033966.4; Medaka Ak2, XM_011481017.3; Human AK3, NM_001199852.2; Mouse Ak3, NM_001365071.1; Medaka Ak3, XM_004074841.4; Human AK4, NM_001005353.3; Mouse Ak4, NM_001177602.1; Medaka Ak4, XM_004068018.4; Human AK5, NM_012093.4, Mouse Ak5, NM_001081277.2; Medaka Ak5, XM_004078698.4; Human AK6, NM_001015891.2; Mouse Ak6, NM_027592.3; Medaka Ak6, XM_004072821.3; Human AK7, NM_001350888.2; Mouse Ak7, NM_030187.1; Medaka Ak7, XM_011490546.3; Medaka LOC101157414, XM_011492034.2; Human AK8, NM_001317958.2; Mouse Ak8, NM_001033874.2; Medaka Ak8, XM_023958761.1; Human AK9, NM_001145128.3; Mouse Ak9, NM_001370813.1; Medaka Ak9, XM_020714548.2

2) While it is clear that the AK1 transgene is expressed from a strong, widely expressed promoter, there is no evidence provided comparing AK1 protein levels or AK1 enzymatic activity in the transgenics and wild types. This would be particularly important information to fully interpret the comparison of the behaviour at the two different temperatures. If technically feasible, such extra information would be invaluable for interpreting the results.

Response: We determined Ak1 protein levels in both Ak1-OE and WT by western blot analysis using the Ak1 antibody.

In both Ak1-OE and WT samples, we observed bands close to the expected band size of medaka Ak1 (21.4 kDa). In addition, we found strong bands at high molecular weights only in Ak1-OE samples. In our overexpression construct, we added a 3× FLAG tag downstream of the Ak1 sequence. Therefore, we expected that the strong bands observed were FLAG-tagged Ak1. To confirm this, we conducted western blot analysis using a FLAG-tag antibody. As expected, we observed bands at the same position as those detected with the Ak1 antibody. From these results, we confirmed Ak1 overexpression at both the gene expression and protein levels. We have added these results in the revised manuscript.

We have also added the following text in the Methods section:

Western blot analysis

Frozen 9 dpf larvae were homogenized and sonicated in 4× Laemmli sample buffer (Bio-Rad, Hercules, CA, USA). Samples were quantified using Pierce 660 nm Protein Assay Reagent (Thermo Fisher Scientific, Waltham, MA, USA). Twenty-five micrograms of protein per sample were separated by SDS-PAGE and transferred onto a PVDF membrane. The PVDF membrane was blocked with 5% skim milk in Tris-buffered saline with Tween 20 (TBST) for 1 h at room temperature. Ak1 polyclonal primary antibody (1:500) (14978-1-AP; Proteintech, Rosemont, IL, USA) was dissolved in 5% skim milk in TBST and incubated for 1 h at room temperature. After washing the membrane with TBST, the membranes were incubated with secondary rabbit antibody (1:1000) (NA934-100UL; GE Healthcare, Chicago, IL, USA) dissolved in 5 % skim milk in TBST for 1 h at room temperature. The membrane was washed with TBST and incubated with ECL prime (GE Healthcare) for 5 min at room temperature and imaged on a LuminoGraph II EM (ATTO, Tokyo, Japan). After eliminating signals using hydrogen peroxide, the membrane was treated with FLAG (DDDDK) tag primary monoclonal antibody (1:1000) (M185-3S; MBL, Nagoya, Japan) followed by secondary mouse antibody (1:1000) (NA931-100UL; GE Healthcare).

Reviewer #2: This manuscript by Maruyama et al. describes the effect of adenylate kinase 1 overexpression on locomotor activity in medaka. The authors found that Ak1-OE increases locomotor activity at a water temperature of 25C in the light period. As such a change did not occur at 15C, the authors suggested the possibility of modulating locomotor activity by Ak1 depending water temperature. This MS was short and well written about well-designed experiments. I have only one question, and changes in locomotor activity may reflect some change in taxis. Did the authors observe any changes in thigmotaxis, scototaxis, geotaxis, etc.

Response: To test whether the increase in locomotor activity of Ak1-OE was due to changes in some taxis, we conducted several additional behavioral tests. When we examined changes in thigmotaxis between Ak1-OE and WT as described by Schnorr et al. [18], no difference was observed. We also conducted a light-dark tank test and a novel tank test for scototaxis and geotaxis, respectively. However, we found no difference between Ak1-OE and WT in these tests, suggesting that Ak1 indeed affects locomotor activity but not taxis. We have added these results to S1 Fig: Comparison of thigmotaxis, scototaxis, and geotaxis between Ak1-OE and WT.

(A) Schematic drawing of thigmotaxis measurement test. (B) Results of thigmotaxis measurement test (n = 11 each). (C) Schematic of light-dark tank test. (D) Results of light-dark tank test (n = 8 each). (E) Schematic representation of the novel tank test. (F) Results of the novel tank test (n = 8 each). All data are presented as the mean ± SEM. The p-value was calculated using a two-tailed Welch’s t-test. Each dot represents an individual value.

We have also added the following text in the Methods section:

To examine thigmotaxis, we referred to Schnorr et al. [18]. In brief, larvae were transferred to a 24-well round plate (Nunclon Delta Surface; Thermo Fisher Scientific, Waltham, MA, USA) at 8 dpf. The plate was then installed in a DanioVision Observation Chamber at 9 dpf. After 6 min of acclimation phase (light on), the lights were kept off for 4 min and activities were recorded. The experiments were conducted from 10:00 to 12:00 at 9 dpf.

To examine scototaxis and geotaxis, we conducted a light-dark tank test and a novel tank test, respectively [19]. In these assays, adult fish (> 6 months) were used. For the novel tank test, each fish was introduced into a glass tank (100 mm width × 65 mm depth × 142 mm height) filled with water to a height of 100 mm. Recordings were started immediately after transferring the fish and lasted for 7 min. We excluded the first 1 min from the analysis. For the light-dark tank test, a plastic container (150 mm width × 100 mm depth × 55 mm height) was used. The container was divided into two equal-sized sections, colored either white or black. Fish were placed in the light area and allowed to move freely between the dark and light areas for 16 min. We excluded the first 1 min from the analysis.

Response to Academic Editor:

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

Response: We have revised the manuscript according to the guidelines of PLOS ONE as suggested.

2. To comply with PLOS ONE submissions requirements, in your Methods section, please provide additional information on the animal research and ensure you have included details on (1) methods of sacrifice, (2) methods of anesthesia and/or analgesia, and (3) efforts to alleviate suffering.

Response: We added the following text on “Ethics statement for animal experiments” in the Methods section:

Animals were euthanized with ethyl 3-aminobenzoate methanesulfonate (MS-222) before sampling. All efforts were made to minimize animal suffering.

3. Thank you for stating in your Funding Statement:

[This work was supported in part by a JSPS KAKENHI “Grant-in-Aid for Scientific Research (S)” (19H05643) for T.Y. and the Sasakawa Scientific Research Grant from The Japan Science Society for M.M.]

Please provide an amended statement that declares *all* the funding or sources of support (whether external or internal to your organization) received during this study, as detailed online in our guide for authors at http://journals.plos.org/plosone/s/submit-now. Please also include the statement “There was no additional external funding received for this study.” in your updated Funding Statement.

Please include your amended Funding Statement within your cover letter. We will change the online submission form on your behalf.

Response: We have changed the original statement to:

This work was supported by a JSPS KAKENHI “Grant-in-Aid for Scientific Research (S)” (19H05643) for T.Y. and the Sasakawa Scientific Research Grant from The Japan Science Society for M.M. There was no additional external funding received for this study. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

4. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

Response: We have amended as follows:

All relevant data are within the manuscript and its Supporting Information files.

5. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels.

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions.

Response: We have uploaded the blot/gel image file (S1_raw_images) as a Supporting Information file.

Attachment

Submitted filename: Response_to_Reviewers.docx

Decision Letter 1

Hubert Vaudry

23 Dec 2021

Adenylate kinase 1 overexpression increases locomotor activity in medaka fish

PONE-D-21-29550R1

Dear Dr. Yoshimura,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Hubert Vaudry

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: I Don't Know

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Nicholas S. Foulkes

Acceptance letter

Hubert Vaudry

26 Dec 2021

PONE-D-21-29550R1

Adenylate kinase 1 overexpression increases locomotor activity in medaka fish

Dear Dr. Yoshimura:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Hubert Vaudry

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. Comparison of thigmotaxis, scototaxis, and geotaxis between Ak1-OE and WT.

    (A) Schematic drawing of thigmotaxis measurement test. (B) Results of thigmotaxis measurement test (n = 11 each). (C) Schematic of light-dark tank test. (D) Results of light-dark tank test (n = 8 each). (E) Schematic representation of the novel tank test. (F) Results of the novel tank test (n = 8 each). All data are presented as the mean ± SEM. The p-value was calculated using a two-tailed Welch’s t-test. Each dot represents an individual value.

    (TIF)

    S1 Raw images

    (PDF)

    Attachment

    Submitted filename: Response_to_Reviewers.docx

    Data Availability Statement

    All relevant data are within the paper and its Supporting Information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES